This research study is studying the effects of adding a certain type of immunotherapy to standard bladder-directed radiation as a treatment for muscle-invasive urothelial carcinoma of the bladder. The drug in this study is: Avelumab (also known as BAVENCIO®)
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational drug to learn whether the drug works in treating a
specific disease. Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved the use of avelumab and
bladder-directed radiation together for this specific disease but avelumab has been approved
for other uses.
While bladder-directed radiation is a standard treatment option for muscle-invasive
urothelial carcinoma of the bladder, the use of avelumab in combination with bladder
radiation in patients with urothelial carcinoma of the bladder is investigational. Radiation
is used in the treatment of muscle-invasive bladder cancer, and avelumab has been approved by
the FDA in patients with more advanced stages of this disease. Avelumab is a form of
immunotherapy, which means it is designed to help the immune system fight cancer cells
together with standard cancer treatments like radiation. Avelumab is currently approved by
the FDA for the treatment of metastatic Merckel cell carcinoma (mMCC) and platinum-refractory
metastatic urothelial carcinoma.
The purpose of this study is to test whether the combination of immunotherapy and bladder
directed radiation is effective in treating muscle-invasive bladder cancer. The study will
also measure other outcomes such as participant's overall health and quality of life during
and after treatment. In addition, the investigators will determine if certain biomarkers are
correlated with outcomes following treatment with immunotherapy and radiation.
|Overal Status||Start Date||Phase||Study Type|
|Recruiting||December 13, 2018||Phase 2||Interventional|
Primary Outcome 1 - Measure: Complete clinical response rate
Primary Outcome 1 - Time Frame: 3 months
Subjects must meet all of the following applicable inclusion criteria to participate in the
- Histologically confirmed transitional cell (urothelial) carcinoma of the bladder that
is invasive into the muscularis propria (≥T2 disease) within 6 months of enrollment
date. The presence of variant histologies (squamous, adenocarcinoma, micropapillary,
etc.) is allowed. Note: A prior diagnosis of non-muscle-invasive bladder cancer (≤T1)
managed with transurethral resection with or without intravesicular therapy (now with
muscle invasion) is allowed.
- Inability to receive cisplatin-based chemotherapy, as defined by creatinine clearance
<60 ml/min, ECOG PS ≤2, grade 2 or higher hearing loss, NYHA class 3 or higher,
neuropathy (grade 2 or higher), or patient refusal to receive cisplatin-based
Additional Inclusion Criteria:
- Male or female subjects aged ≥18 years
- ECOG performance status ≤2 or Karnofsky score ≥60% (see Appendix A)
- Life expectancy of greater than 1 year
- Demonstrate normal organ and marrow function
- Women of child-bearing age must have a negative serum pregnancy test at screening.
- Women of child-bearing potential and men must agree to use a highly effective method
of contraception (hormonal or barrier method of birth control, or abstinence)
beginning prior to study entry, for the duration of study participation, and for at
least 30 days after last avelumab treatment administration if the risk of conception
- Ability to understand and willingness to sign a written informed consent document
- Prior intravenous therapy for treatment of bladder cancer
- Prior pelvic radiation
- Any component of small cell histology in the bladder biopsy
- Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment
- Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,
inhaled, topical steroid, or local steroid injection (e.g., intra-articular
injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone
or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT
scan premedication) are allowed.
- History of another malignancy within 5 years prior to randomization except for:
non-muscle-invasive bladder cancer (i.e., ≤T1), completely resected basal cell or
squamous cell skin cancer, completed resected carcinoma-in-situ of any site, or
localized prostate cancer managed definitively with a non-radiation based approach.
Additional Exclusion Criteria:
- Evidence of lymph node involvement or metastatic disease on CT of the chest, abdomen,
and pelvis. To be considered positive, a lymph node must measure >15 mm in short axis.
- Clinically significant (i.e. active) cardiovascular disease: symptomatic congestive
heart failure (≥ New York Heart Association Classification Class II), unstable angina
pectoris, serious cardiac arrhythmia requiring medication, or CVA/stroke/MI (< 6
months prior to enrollment)
- Known prior severe hypersensitivity to investigational product or any component in its
formulations, including known severe hypersensitivity reactions to monoclonal
antibodies (NCI CTCAE v4.03 Grade ≥ 3)
- Breast feeding women who are unwilling to stop breastfeeding during treatment and for
at least one month after the duration of treatment
- Patients with known history of testing positive for HIV or known acquired
- Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory
agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid
diseases not requiring immunosuppressive treatment are eligible.
- Active infection requiring intravenous antibiotic therapy
- Vaccination within 4 weeks of the first dose of avelumab and while on trial is
prohibited except for administration of inactivated vaccines
- Major surgery within the last 30 days (with the exception of TURBT).
- Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive
HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)
- Prior organ transplantation including allogenic stem-cell transplantation
- Patient is unwilling to stop (or wishes to start) taking herbal and natural remedies
that may have immune-modulating effects during the study period
- Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however,
alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety
risk based on investigator's judgment are acceptable
- Other severe acute or chronic medical conditions including immune colitis,
inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric
conditions including recent (within the past year) or active suicidal ideation or
behavior; or laboratory abnormalities that may increase the risk associated with study
participation or study treatment administration or may interfere with the
interpretation of study results and, in the judgment of the investigator, would make
the patient inappropriate for entry into this study.
- Pregnant women are excluded from this study.
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Name: Kent Mouw, MD, PhD
Role: Principal Investigator
Affiliation: Brigham and Women's Hospital
Name: Kent Mouw, MD, PhD
|Dana-Farber Cancer Institute
Boston, Massachusetts 02115
Kent Mouw, MD, PhD
|Brigham and Women's Hospital
Boston, Massachusetts 02215
Kent Mouw, MD, PhD